Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA issues guidance on "child" definition for PMAs (Pre-market Approvals):

This article was originally published in Clinica

Executive Summary

The FDA has issued a final guidance on premarket submissions for devices intended for children. Initially released in draft form in July 2003, the revised document now clarifies the distinction between state and federal law pertaining to the age of consent to the clinical definition of the paediatric population. It continues to define adolescent as aged 12 to 21, even though some paediatric devices include labelling that puts the upper age limit for a child at age 18. The FDA explained that its age descriptions are somewhat arbitrary, and that other factors, such as the weight, body size and physiological and neurological development, may be more appropriate indicators.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058565

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel